scholarly journals Severe Multiorgan Failure Following Yellow Fever Vaccination

Vaccines ◽  
2020 ◽  
Vol 8 (2) ◽  
pp. 249 ◽  
Author(s):  
Cristina Domingo ◽  
Judith Lamerz ◽  
Daniel Cadar ◽  
Marija Stojkovic ◽  
Philip Eisermann ◽  
...  

Background: The yellow fever (YF) vaccination is recommended by the WHO for people traveling or living in endemic areas at risk for yellow fever infections in Africa and South America. Although the live attenuated yellow fever vaccine is a safe and efficient vaccine, rare serious adverse events after vaccination have been reported. Case presentation: We present the case of a 74-year-old male with multiorgan failure after yellow fever vaccination for a trip to Brazil. The patient required admission to the intensive care unit with a prolonged stay due to severe organ dysfunction. Five days after the YF vaccination, the patient experienced nausea, vomiting, diarrhea, and general illness. Three days later he sought medical attention and was transferred to the University Hospital Heidelberg with beginning multiorgan failure and severe septic shock, including hypotonia, tachypnea, thrombopenia, and acute renal failure the same day. Within one week after vaccination, antibodies against YF virus were already detectable and progressively increased over the next two weeks. Viral RNA was detected in serum on the day of admission, with a viral load of 1.0 × 105 copies/mL. The YF virus (YFV) RNA was also present in tracheal secretions for several weeks and could be detected in urine samples up to 20 weeks after vaccination, with a peak viral load of 1.3 × 106 copies/mL. After 20 weeks in the ICU with nine weeks of mechanical ventilation, the patient was transferred to another hospital for further recovery. Conclusions: The risk for severe adverse events due to the YF vaccination should be balanced against the risk of acquiring a severe YF infection, especially in elderly travelers.

Vaccine ◽  
2011 ◽  
Vol 29 (28) ◽  
pp. 4544-4555 ◽  
Author(s):  
Roger E. Thomas ◽  
Diane L. Lorenzetti ◽  
Wendy Spragins ◽  
Dave Jackson ◽  
Tyler Williamson

2020 ◽  
Vol 7 (4) ◽  
pp. e726 ◽  
Author(s):  
Angela Huttner ◽  
Gilles Eperon ◽  
Agustina M. Lascano ◽  
Serge Roth ◽  
Jean-Marc Schwob ◽  
...  

ObjectiveTo determine whether live-attenuated yellow fever vaccine (YFV) was associated with MS relapse, we evaluated the clinical courses of 23 patients in the year before and the year after immunization at the university hospital of Geneva, Switzerland.MethodsThis self-controlled retrospective cohort included adult patients with MS receiving YFV between 2014 and 2018 and defined the year before vaccination, the 3 months thereafter, and the 9 months following as the pre-exposure (PEP), exposure-risk (ERP), and postrisk (PRP) periods, respectively. The primary outcome was the relative incidence of relapse in the ERP vs the PEP. Secondary end points included the presence of new T2-weighted (T2) or T1-weighted gadolinium-positive (T1Gd+) MRI lesions.ResultsOf 23 patients with MS receiving YFV (20 relapsing MS and 3 primary progressive MS), 17 (74%) were women; mean age was 34 years (SD ±10); and 10 of 23 (40%) were treated with disease-modifying therapies (DMTs). Although 9 patients experienced 12 relapses in the PEP, only one experienced a relapse in the ERP; 3 other patients experienced one relapse each in the PRP. None of the 8 patients receiving natalizumab at the time of vaccination experienced relapse thereafter. In the PEP, ERP, and PRP, 18, 2, and 9 patients had new brain and/or spinal cord lesions on T2 or T1Gd + MRI, respectively.ConclusionsIn this cohort, YF vaccination was associated with neither an increase in MS relapse nor emergence of brain and/or spinal lesions. Further studies are warranted to confirm these findings.Classification of evidenceThis study provides Class IV evidence that for persons with MS, YFV may not increase relapse risk.


Author(s):  
Mariângela Ottoboni Brunaldi ◽  
René Julias Costa Silva ◽  
Alexandre Todorovic Fabro ◽  
Daniel Cardoso de Almeida e Araujo ◽  
Anibal Basile-Filho ◽  
...  

Yellow fever is a viral hemorrhagic disease, and vaccination is the most effective way to minimize the impact of the disease. Serious adverse events after yellow fever vaccination are rare. We report the case of a young woman with an unusual presentation of yellow fever 17DD vaccine-associated acute viscerotropic disease, with severe hepatic impairment following a long incubation period. She died more than a month after yellow fever vaccination.


2011 ◽  
Vol 6 (3) ◽  
pp. 145-154 ◽  
Author(s):  
Roger E. Thomas ◽  
Diane L. Lorenzetti ◽  
Wendy Spragins ◽  
Dave Jackson ◽  
Tyler Williamson

Vaccine ◽  
2005 ◽  
Vol 23 (25) ◽  
pp. 3256-3263 ◽  
Author(s):  
Alena Y. Khromava ◽  
Rachel Barwick Eidex ◽  
Leisa H. Weld ◽  
Katrin S. Kohl ◽  
Robert D. Bradshaw ◽  
...  

2015 ◽  
Vol 11 (9) ◽  
pp. 2183-2187 ◽  
Author(s):  
Reinaldo de Menezes Martins ◽  
Maria da Luz Fernandes Leal ◽  
Akira Homma

2021 ◽  
pp. 135245852110063
Author(s):  
Caroline Papeix ◽  
Julie Mazoyer ◽  
Elisabeth Maillart ◽  
Caroline Bensa ◽  
Anne-Laure Dubessy ◽  
...  

Background: Yellow fever vaccine (YFV) is not advised for multiple sclerosis (MS) patients because of the potential risk of post-vaccine relapses. Objective: To assess the risk of relapsing-remitting multiple sclerosis (RR-MS) worsening after YFV. Methods: Non-interventional observational retrospective, exposed/non-exposed cohort study nested in the French national cohort including MS. Results: 128 RR-MS were included. The 1-year annualized relapse rate (ARR) following YFV did not differ between exposed: 0.219 (0.420) and non-exposed subjects: 0.208 (0.521) ( p = 0.92). Time to first relapse was not different between groups (adjusted hazard ratio (HR) = 1.33; 95% confidence interval (CI) = 0.53–3.30, p = 0.54). Conclusion: These results suggest that YFV does not worsen the course of RR-MS.


Sign in / Sign up

Export Citation Format

Share Document